The search for more selective, effective and targeted cancer therapies continues to drive innovation across medicinal chemistry and pharmaceutical research. Heterocyclic Chemistry in Oncology: Promising Agents and Novel Approaches, edited by Smriti Dewangan, Anchal Verma and Varsha Rawat, explores the important role of heterocyclic compounds in modern anticancer drug discovery and development.
Bringing together perspectives from medicinal chemistry, molecular oncology, computational biology and pharmaceutical sciences, the book examines how diverse heterocyclic scaffolds are being investigated as potential anticancer agents. It begins with the fundamental principles of heterocyclic chemistry and cancer biology before exploring important classes of bioactive heterocycles, including pyrimidines, imidazoles, triazoles, quinolines, indoles, pyrazoles, thiazoles and fused heterocyclic systems.
The book addresses the synthesis and biological evaluation of these compounds alongside structure activity relationships, molecular targets and mechanisms of action. It also examines emerging approaches shaping contemporary oncology research, including molecular docking, artificial intelligence-assisted drug discovery, nanotechnology-enabled drug delivery, targeted therapies and kinase inhibitors.
By connecting synthetic chemistry with biological evaluation and translational research, the book provides a broad view of both established drug candidates and emerging approaches in heterocycle-based cancer therapeutics. It also considers the challenges involved in translating promising compounds into clinical applications and identifies areas for future research.
About the Editors
Smriti Dewangan, Anchal Verma and Varsha Rawat have brought together a multidisciplinary collection examining the intersection of heterocyclic chemistry and oncology. Their editorial approach connects chemical design and synthesis with biological evaluation, computational approaches, therapeutic targeting and the broader challenges of anticancer drug development.
Key Features
- Detailed coverage of major heterocyclic scaffolds used in anticancer drug discovery
- Discussion of pyrimidines, imidazoles, triazoles, quinolines, indoles, pyrazoles, thiazoles and fused heterocyclic systems
- Integrated treatment of synthesis, biological evaluation and structure–activity relationships
- Analysis of molecular targets and mechanisms of action of heterocycle-based anticancer agents
- Coverage of targeted therapies and kinase inhibitors
- Insights into molecular docking and AI-assisted drug discovery
- Discussion of nanotechnology-enabled drug delivery approaches
- Examination of challenges and future opportunities for clinical translation
Who Should Read This Book?
The book will be useful to medicinal chemists, pharmaceutical scientists, cancer researchers, academic faculty, and postgraduate students working in medicinal chemistry, pharmaceutical chemistry, drug discovery and oncology research.
Explore the book: https://bit.ly/4yKXQbm